Which has higher earnings and valuation, HYPR or BWAY?

Brainsway has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hyperfine $11.40M 11.71 -$35.57M -$0.41 N/A Brainsway $52.22M 11.77 $7.57M $0.35 43.77

Is HYPR or BWAY more profitable?

Brainsway has a net margin of 15.68% compared to Hyperfine's net margin of -226.88%. Brainsway's return on equity of 12.28% beat Hyperfine's return on equity. Company Net Margins Return on Equity Return on Assets Hyperfine -226.88% -98.83% -67.09% Brainsway 15.68% 12.28% 7.75%

Does the media prefer HYPR or BWAY?

In the previous week, Hyperfine had 1 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for Hyperfine and 3 mentions for Brainsway. Brainsway's average media sentiment score of 1.10 beat Hyperfine's score of 0.93 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperfine 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Brainsway 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HYPR or CLPT?

In the previous week, Hyperfine had 2 more articles in the media than ClearPoint Neuro. MarketBeat recorded 4 mentions for Hyperfine and 2 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 1.85 beat Hyperfine's score of 0.93 indicating that ClearPoint Neuro is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperfine 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ClearPoint Neuro 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation and earnings, MDXG or HYPR?

MiMedx Group has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiMedx Group $418.63M 1.39 $48.58M $0.20 19.48 Hyperfine $11.40M 11.71 -$35.57M -$0.41 N/A

Is MDXG or HYPR more profitable?

MiMedx Group has a net margin of 7.88% compared to Hyperfine's net margin of -226.88%. MiMedx Group's return on equity of 21.03% beat Hyperfine's return on equity. Company Net Margins Return on Equity Return on Assets MiMedx Group 7.88% 21.03% 15.92% Hyperfine -226.88% -98.83% -67.09%

Does the media favor MDXG or HYPR?

In the previous week, Hyperfine had 2 more articles in the media than MiMedx Group. MarketBeat recorded 4 mentions for Hyperfine and 2 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.93 equaled Hyperfine'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hyperfine 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, NPCE or HYPR?

NeuroPace has higher revenue and earnings than Hyperfine. NeuroPace is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroPace $99.99M 5.32 -$21.47M -$0.65 N/A Hyperfine $11.40M 11.71 -$35.57M -$0.41 N/A

Is NPCE or HYPR more profitable?

NeuroPace has a net margin of -21.67% compared to Hyperfine's net margin of -226.88%. Hyperfine's return on equity of -98.83% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets NeuroPace -21.67% -108.20% -18.50% Hyperfine -226.88% -98.83% -67.09%

Does the media prefer NPCE or HYPR?

In the previous week, Hyperfine had 1 more articles in the media than NeuroPace. MarketBeat recorded 4 mentions for Hyperfine and 3 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.57 beat Hyperfine's score of 0.93 indicating that NeuroPace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Hyperfine 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KIDS or HYPR?

In the previous week, OrthoPediatrics and OrthoPediatrics both had 4 articles in the media. Hyperfine's average media sentiment score of 0.93 beat OrthoPediatrics' score of 0.41 indicating that Hyperfine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OrthoPediatrics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hyperfine 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Hyperfine (HYPR) Competitors

$1.34 -0.01 (-0.37%)

As of 03:56 PM Eastern

Compare

HYPR vs. BWAY, CLPT, MDXG, NPCE, and KIDS

Should you buy Hyperfine stock or one of its competitors? MarketBeat compares Hyperfine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hyperfine include Brainsway (BWAY), ClearPoint Neuro (CLPT), MiMedx Group (MDXG), NeuroPace (NPCE), and OrthoPediatrics (KIDS). These companies are all part of the "medical equipment" industry.

How does Hyperfine compare to Brainsway?

Hyperfine (NASDAQ:HYPR) and Brainsway (NASDAQ:BWAY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Brainsway has a net margin of 15.68% compared to Hyperfine's net margin of -226.88%. Brainsway's return on equity of 12.28% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
Brainsway	15.68%	12.28%	7.75%

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 26.3% of Hyperfine shares are held by company insiders. Comparatively, 19.0% of Brainsway shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Brainsway has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	11.71	-$35.57M	-$0.41	N/A
Brainsway	$52.22M	11.77	$7.57M	$0.35	43.77

In the previous week, Hyperfine had 1 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for Hyperfine and 3 mentions for Brainsway. Brainsway's average media sentiment score of 1.10 beat Hyperfine's score of 0.93 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainsway	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hyperfine presently has a consensus target price of $1.78, suggesting a potential upside of 32.59%. Brainsway has a consensus target price of $16.00, suggesting a potential upside of 4.45%. Given Hyperfine's higher possible upside, equities research analysts plainly believe Hyperfine is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Hyperfine has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Summary

Brainsway beats Hyperfine on 11 of the 15 factors compared between the two stocks.

How does Hyperfine compare to ClearPoint Neuro?

Hyperfine (NASDAQ:HYPR) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 26.3% of Hyperfine shares are held by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Hyperfine currently has a consensus target price of $1.78, indicating a potential upside of 32.59%. ClearPoint Neuro has a consensus target price of $23.00, indicating a potential upside of 22.63%. Given Hyperfine's higher probable upside, analysts plainly believe Hyperfine is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

ClearPoint Neuro has higher revenue and earnings than Hyperfine. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	11.71	-$35.57M	-$0.41	N/A
ClearPoint Neuro	$36.97M	15.21	-$25.54M	-$1.01	N/A

ClearPoint Neuro has a net margin of -71.57% compared to Hyperfine's net margin of -226.88%. Hyperfine's return on equity of -98.83% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

In the previous week, Hyperfine had 2 more articles in the media than ClearPoint Neuro. MarketBeat recorded 4 mentions for Hyperfine and 2 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 1.85 beat Hyperfine's score of 0.93 indicating that ClearPoint Neuro is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ClearPoint Neuro	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Hyperfine has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

Summary

Hyperfine beats ClearPoint Neuro on 8 of the 15 factors compared between the two stocks.

How does Hyperfine compare to MiMedx Group?

MiMedx Group (NASDAQ:MDXG) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

MiMedx Group has a net margin of 7.88% compared to Hyperfine's net margin of -226.88%. MiMedx Group's return on equity of 21.03% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
Hyperfine	-226.88%	-98.83%	-67.09%

MiMedx Group presently has a consensus target price of $8.50, indicating a potential upside of 118.23%. Hyperfine has a consensus target price of $1.78, indicating a potential upside of 32.59%. Given MiMedx Group's stronger consensus rating and higher probable upside, equities analysts clearly believe MiMedx Group is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 15.0% of Hyperfine shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by insiders. Comparatively, 26.3% of Hyperfine shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

MiMedx Group has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Hyperfine has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

MiMedx Group has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.39	$48.58M	$0.20	19.48
Hyperfine	$11.40M	11.71	-$35.57M	-$0.41	N/A

In the previous week, Hyperfine had 2 more articles in the media than MiMedx Group. MarketBeat recorded 4 mentions for Hyperfine and 2 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.93 equaled Hyperfine'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperfine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MiMedx Group beats Hyperfine on 12 of the 15 factors compared between the two stocks.

How does Hyperfine compare to NeuroPace?

NeuroPace (NASDAQ:NPCE) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

NeuroPace has higher revenue and earnings than Hyperfine. NeuroPace is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	5.32	-$21.47M	-$0.65	N/A
Hyperfine	$11.40M	11.71	-$35.57M	-$0.41	N/A

NeuroPace has a net margin of -21.67% compared to Hyperfine's net margin of -226.88%. Hyperfine's return on equity of -98.83% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.67%	-108.20%	-18.50%
Hyperfine	-226.88%	-98.83%	-67.09%

NeuroPace has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market. Comparatively, Hyperfine has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

In the previous week, Hyperfine had 1 more articles in the media than NeuroPace. MarketBeat recorded 4 mentions for Hyperfine and 3 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.57 beat Hyperfine's score of 0.93 indicating that NeuroPace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Hyperfine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroPace currently has a consensus target price of $18.83, suggesting a potential upside of 20.80%. Hyperfine has a consensus target price of $1.78, suggesting a potential upside of 32.59%. Given Hyperfine's higher probable upside, analysts plainly believe Hyperfine is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

78.8% of NeuroPace shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 20.5% of NeuroPace shares are held by company insiders. Comparatively, 26.3% of Hyperfine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

NeuroPace beats Hyperfine on 10 of the 17 factors compared between the two stocks.

How does Hyperfine compare to OrthoPediatrics?

OrthoPediatrics (NASDAQ:KIDS) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Hyperfine has lower revenue, but higher earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$236.35M	2.09	-$39.65M	-$1.68	N/A
Hyperfine	$11.40M	11.71	-$35.57M	-$0.41	N/A

In the previous week, OrthoPediatrics and OrthoPediatrics both had 4 articles in the media. Hyperfine's average media sentiment score of 0.93 beat OrthoPediatrics' score of 0.41 indicating that Hyperfine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OrthoPediatrics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hyperfine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OrthoPediatrics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Hyperfine has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

OrthoPediatrics has a net margin of -16.31% compared to Hyperfine's net margin of -226.88%. OrthoPediatrics' return on equity of -7.01% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-16.31%	-7.01%	-4.86%
Hyperfine	-226.88%	-98.83%	-67.09%

69.1% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 15.0% of Hyperfine shares are owned by institutional investors. 31.8% of OrthoPediatrics shares are owned by company insiders. Comparatively, 26.3% of Hyperfine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

OrthoPediatrics presently has a consensus price target of $24.44, suggesting a potential upside of 26.84%. Hyperfine has a consensus price target of $1.78, suggesting a potential upside of 32.59%. Given Hyperfine's higher possible upside, analysts plainly believe Hyperfine is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

OrthoPediatrics beats Hyperfine on 8 of the 15 factors compared between the two stocks.

Get Hyperfine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYPR vs. The Competition

Export

Metric	Hyperfine	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$134.51M	$7.35B	$6.78B	$12.56B
Dividend Yield	N/A	1.25%	2.66%	6.15%
P/E Ratio	-3.30	50.00	27.45	25.31
Price / Sales	11.71	82.48	581.70	118.43
Price / Cash	N/A	26.23	48.53	58.59
Price / Book	3.20	7.44	10.93	6.62
Net Income	-$35.57M	$159.19M	$3.57B	$336.83M
7 Day Performance	-7.88%	0.90%	2.49%	2.63%
1 Month Performance	-11.51%	-3.34%	1.59%	0.24%
1 Year Performance	95.66%	4.29%	35.83%	29.61%

Hyperfine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYPR Hyperfine	3.2646 of 5 stars	$1.35 -0.4%	$1.78 +32.6%	+87.6%	$134.51M	$11.40M	N/A	190	News Coverage
BWAY Brainsway	3.171 of 5 stars	$14.39 +0.1%	$16.00 +11.2%	+135.9%	$576.92M	$56.22M	41.12	120	Positive News
CLPT ClearPoint Neuro	2.344 of 5 stars	$18.53 +8.6%	$23.00 +24.1%	+49.4%	$555.72M	$36.97M	N/A	110	News Coverage Gap Down
MDXG MiMedx Group	3.8794 of 5 stars	$3.73 +1.6%	$8.50 +127.9%	-37.0%	$555.58M	$418.63M	18.65	870
NPCE NeuroPace	2.3973 of 5 stars	$15.92 +3.6%	$18.83 +18.3%	+42.6%	$542.71M	$99.99M	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYPR) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hyperfine (HYPR) Competitors

HYPR vs. BWAY, CLPT, MDXG, NPCE, and KIDS

How does Hyperfine compare to Brainsway?

Summary

How does Hyperfine compare to ClearPoint Neuro?

Summary

How does Hyperfine compare to MiMedx Group?

Summary

How does Hyperfine compare to NeuroPace?

Summary

How does Hyperfine compare to OrthoPediatrics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPR vs. The Competition

Hyperfine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hyperfine (HYPR) Competitors

HYPR vs. BWAY, CLPT, MDXG, NPCE, and KIDS

How does Hyperfine compare to Brainsway?

Is HYPR or BWAY more profitable?

Do insiders and institutionals believe in HYPR or BWAY?

Which has higher earnings and valuation, HYPR or BWAY?

Does the media prefer HYPR or BWAY?

Do analysts recommend HYPR or BWAY?

Which has more volatility and risk, HYPR or BWAY?

Summary

How does Hyperfine compare to ClearPoint Neuro?

Do institutionals & insiders have more ownership in HYPR or CLPT?

Do analysts prefer HYPR or CLPT?

Which has preferable valuation & earnings, HYPR or CLPT?

Is HYPR or CLPT more profitable?

Does the media prefer HYPR or CLPT?

Which has more volatility and risk, HYPR or CLPT?

Summary

How does Hyperfine compare to MiMedx Group?

Is MDXG or HYPR more profitable?

Do analysts rate MDXG or HYPR?

Do insiders & institutionals have more ownership in MDXG or HYPR?

Which has more risk & volatility, MDXG or HYPR?

Which has higher valuation and earnings, MDXG or HYPR?

Does the media favor MDXG or HYPR?

Summary

How does Hyperfine compare to NeuroPace?

Which has stronger valuation & earnings, NPCE or HYPR?

Is NPCE or HYPR more profitable?

Which has more risk & volatility, NPCE or HYPR?

Does the media prefer NPCE or HYPR?

Do analysts prefer NPCE or HYPR?

Do institutionals & insiders believe in NPCE or HYPR?

Summary

How does Hyperfine compare to OrthoPediatrics?

Which has better earnings & valuation, KIDS or HYPR?

Does the media refer more to KIDS or HYPR?

Which has more volatility & risk, KIDS or HYPR?

Is KIDS or HYPR more profitable?

Do institutionals and insiders hold more shares of KIDS or HYPR?

Do analysts rate KIDS or HYPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPR vs. The Competition

Hyperfine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools